Important Notes This annual report summary is derived from the full annual report. Investors should read the full annual report carefully for a comprehensive understanding of the company's operating results, financial position, and future development plans.
Directors' Attendance at Board Meetings: The following directors did not personally attend the board meeting to review the annual report: Name: Su Qingcan Position: Chairman Reason for Absence: Personal reasons Delegate: Chen Fengguo
The audit opinion of Jincheng Certified Public Accountants (Special General Partnership) on the company's financial report for the year was a standard unqualified opinion.
Non-standard Audit Opinion Reminder □ Applicable Not Applicable The company was not profitable at the time of listing and has not yet achieved profitability. □ Applicable Not Applicable Board Meeting Resolution on Profit Distribution Plan or Capital Reserve Transfer to Share Capital for the Reporting Period ☑ Applicable Not Applicable The profit distribution plan deliberated by the Board of Directors is as follows: Based on the total share capital of the company registered on the equity distribution registration date, excluding the shares in the repurchase securities account, a cash dividend of RMB 1.70 per 10 shares (tax inclusive) will be distributed to all shareholders. No bonus shares will be issued (tax inclusive), and no capital reserve will be transferred to share capital to distribute shares to all shareholders (tax inclusive). Board Resolution on Profit Distribution Plan for Preferred Shares During the Reporting Period □ Applicable Not Applicable
Company Basic Information
-
Company Profile Stock Abbreviation: Huaxia Eye Stock Exchange: Shenzhen Stock Exchange Stock Code: 301267 Contact Person and Contact Information Name: Cao Nai'en Position: Board Secretary Office Address: No. 999, Wutong West Road, Huli District, Xiamen Fax: 0592-2108895 Telephone: 0592-2108975 Email: zhengquanbu@huaxiaeye.com Name: Shen Shihua Position: Securities Affairs Representative Office Address: No. 999, Wutong West Road, Huli District, Xiamen Fax: 0592-2108895 Telephone: 0592-2108975 Email: zhengquanbu@huaxiaeye.com
-
Business Overview for the Reporting Period (1) Main Business of the Company As a leading domestic ophthalmology medical chain group, Huaxia Eye has always adhered to the mission of "serving every patient, regardless of wealth or poverty, and giving everyone a pair of healthy and bright eyes." Upholding the core values of "responsibility, care, innovation, and win-win," the company provides comprehensive ophthalmology diagnosis and treatment services to the public, covering eight sub-specialties including cataract, refractive, fundus, strabismus and pediatric ophthalmology, ocular surface, glaucoma, orbital and ocular tumors, and ocular trauma, as well as optometry. The company's affiliated Xiamen Eye Center is a national Class III Grade A specialized hospital and a national key clinical specialty (ophthalmology) construction unit. It also houses a postdoctoral research station and an academician expert workstation. Based on the benchmark model of Xiamen Eye Center, the company continues to promote its chain layout, initially establishing a nationwide network of diagnosis and treatment service outlets. In 2024, it successfully acquired Chengdu Aidi Eye Hospital (a Class III Grade A specialized hospital), becoming a large medical chain group with "double Class A" ophthalmology hospitals.
Future Outlook Looking ahead, the company will continue to adhere to the strategy of "organic growth + external expansion," upholding the concept of integrated development of medicine, teaching, and research to continuously improve the national ophthalmology medical network layout, drive sustained growth in operating performance, and provide patients with advanced, reasonably priced, and convenient high-quality ophthalmology diagnosis and treatment services.